• Earlier this week, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY (paltusotine), an oral somatostatin receptor type 2 agonist for treating adult acromegaly, supported by data from 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints.
• This move extends PALSONIFY’s global reach beyond its existing US approval and recent positive European CHMP opinion, underscoring Crinetics’ push to position the once-daily oral therapy as a new option for acromegaly care across major markets.
• We’ll now examine how the Brazil filing for PALSONIFY, backed by extensive Phase 3 data, could influence Crinetics Pharmaceuticals’ investment narrative.

Find 61 companies with promising cash flow potential yet trading below their fair value.

Crinetics Pharmaceuticals Investment Narrative Recap

To own Crinetics today, you need to believe PALSONIFY can scale from an early US launch into a durable, multi region acromegaly franchise while the broader endocrine pipeline matures. The Brazil MAA filing adds another potential geography, but it does not change the near term focus on US launch uptake, which remains the key catalyst, nor does it remove the main risk of continued heavy cash burn against limited current product revenue.

Among recent updates, the resignation of Chief Development and Operating Officer Jeff Knight is the one investors may want to keep in mind alongside the Brazil news. While the company says responsibilities will be reassigned internally, leadership transitions in development and operations sit close to the heart of both PALSONIFY’s global rollout and the advancement of paltusotine in carcinoid syndrome and other late stage programs.

Yet behind the Brazil filing, investors should still be aware that the biggest risk is the company’s ongoing cash burn and...

Crinetics Pharmaceuticals' narrative projects $454.3 million revenue and $94.8 million earnings by 2029. This requires 566.4% yearly revenue growth and a $517.9 million earnings increase from $-423.1 million today.

Uncover how Crinetics Pharmaceuticals' forecasts yield a $82.43 fair value, a 145% upside to its current price.

Exploring Other Perspectives

Before this Brazil filing, the most optimistic analysts were assuming revenue could reach about US$534.2 million by 2028, a far more ambitious path than consensus, which highlights how differently you and other shareholders might weigh early PALSONIFY uptake against the risk that trial setbacks across paltusotine and Atumelnant could still derail that story.

Explore 4 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.